Table 5.

Efficacy and Tolerability of Aimovig and Topamax in the last 3 months of the treatment.

	Efficacy							Tolerability
Comparative Groups		n	Mean	Skewness		Kurtosis
				Statistics	Standard Error	Statistics	Standard Error
Erenumab	A 50% reduction in MIDAS scores in the last 3 months	52	3.76	1.275	0.33	0.41	0.65	100%
Topiramate	A 50% reduction in MIDAS scores in the last 3 months	56	5.89	0.52	0.32	0.56	0.63	14.02%